Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Indiana for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Indiana only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Indiana (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Mohamed Farhat (NPI 1104082809)

Field	Value
Entity Type	Individual
Organization	Mohamed Farhat
Address	5340 Holy Cross Pkwy
City	Mishawaka
State	IN
ZIP	46545
Taxonomy	Medical Oncology Physician
NPI Enumerated	August 1, 2008

Payer Source	Total Paid
Medicare	$2.2M
Medicaid	$0

Key Findings

This provider’s revenue is concentrated almost entirely in Medicare: total Medicare revenue is $2.2M and there is no Medicaid billing on file, making the practice effectively single‑payer from a public-payor perspective. Absence of any Medicaid activity suggests payer mix is heavily weighted toward Medicare beneficiaries rather than dual- or Medicaid-dominant panels.

Revenue concentration is high: the precomputed top-3 Medicare codes (J9271, J9299, J0897) account for 80.4% of the provider’s total Medicare revenue. Those three codes individually generated $928.8K (J9271, 42.7%), $525.1K (J9299, 24.1%), and $295.3K (J0897, 13.6%), indicating a small number of drug/infusion codes drive the majority of receipts.

The code mix and volumes point to an infusion-centered oncology practice focused on checkpoint inhibitors and supportive bone therapy: J9271 (pembrolizumab) has 21.6K claims, J9299 (nivolumab) has 21.9K claims, and J0897 (denosumab) has 15.5K claims, which together dominate revenue. Complementary codes for chemotherapy administration (96413, 96417, 96402) and E/M visits (99214, 99215, 99205) further indicate that the provider administers oncology infusions on-site and manages evaluation/management for established and new patients.

Competitive standing varies by product: for J9271 the provider ranks #320 of 1841 providers nationally (82th percentile; typical, unremarkable volume for this code), and for J9299 the provider ranks #141 of 505 providers nationally (72th percentile; typical, unremarkable volume for this code), suggesting modest-to-typical national participation in first‑line checkpoint inhibitor billing. By contrast, J0897 ranks #493 of 10057 providers nationally (95th percentile; notably above typical national volume), indicating a relatively strong national position for denosumab administration compared with peers.

Visit-level E/M activity is materially above peers for higher-complexity encounters: 99214 shows 980 claims and $83.3K revenue and ranks #12002 of 479517 providers nationally (97th percentile; notably above typical national volume), while 99215 shows 386 claims and $50.6K revenue and ranks #3505 of 145531 providers nationally (98th percentile; notably above typical national volume). High volumes in 99205 (111 claims, ranks #2378 of 66257, 96th percentile; notably above typical national volume) reinforce that the provider bills substantial high-complexity outpatient evaluation and management.

Infusion and administration procedure volumes support an active infusion operation: 96413 has 521 claims ($49K revenue) and ranks #616 of 7514 providers nationally (92th percentile; typical, unremarkable volume), and 96372 has 477 claims ($4.8K revenue) and ranks #1784 of 58224 providers nationally (97th percentile; notably above typical national volume). These procedure-level patterns are consistent with frequent on-site drug administration and sequential/adjunct infusion events.

Tenure is long enough to suggest an established practice footprint: the NPI was enumerated on 2008-08-01 (~18 years ago), indicating sustained Medicare billing activity over nearly two decades. That tenure, combined with high counts for branded immunotherapy claims, suggests consistent specialty practice rather than short-term or recently opened operations.

From an operational and financial risk perspective, the practice is highly dependent on a narrow set of high-cost injectable therapies: with the top three codes accounting for 80.4% of Medicare revenue and total Medicare revenue at $2.2M, changes in utilization or reimbursement for J9271, J9299, or J0897 would likely have an outsized impact on receipts. The lack of Medicaid billing also means there is no visible state‑program revenue diversification to mitigate payer-specific payment shifts.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

43 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	21,600	$40	$928.8K
J9299	Injection, nivolumab, 1 mg	21,880	$20	$525.1K
J0897	Injection, denosumab, 1 mg	15,540	$20	$295.3K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	980	$90	$83.3K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	1,960	$40	$70.6K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	27,680	$1	$55.4K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	390	$130	$50.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	520	$90	$49K
J9394	Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg	520	$30	$17.7K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	110	$160	$17.5K

Showing 1–10 of 43

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 43 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Indiana Distribution

Mohamed Farhat — 8 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Indiana

Full comparison — all codes billed, vs. state median

43 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	5	20	11,200	$40	$631.7K
J9299	1	10	21,700	$20	$498.3K
J0897	9	220	2,730	$20	$74.9K
Q5115	1	10	1,640	$30	$56.3K
J0881	4	10	20,080	$1	$47.4K
96413	8	120	140	$90	$19.1K
J9394	1	10	520	$30	$17.6K
99214	174	10,540	110	$80	$15.5K
99233	1,517	2,720	80	$90	$13.4K
J3490	4	40	50	$180	$12.8K

Showing 1–10 of 43

Related Providers

Other providers that share a Tax Identification Number (TIN) with Mohamed Farhat, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Enric Solans	IL	Anatomic Pathology & Clinical Pathology Physician	$58.5K	$7.9M
Lake Hospital System Inc	OH	Family Medicine Physician	$0	$6.9M
Samer Dola	WI	Hematology (Pathology) Physician	$103.3K	$5.8M
Michael Blair	IL	Retina Specialist (Ophthalmology) Physician	$3M	$2.6M
Mazen Rachid	IL	Pediatrics Physician	$0	$5.1M
Aaron Weinberg	IL	Retina Specialist (Ophthalmology) Physician	$3.3M	$1.2M
Zac Ravage	IL	Retina Specialist (Ophthalmology) Physician	$4.2M	$167.5K
Jack Cohen	IL	Retina Specialist (Ophthalmology) Physician	$3.8M	$445.2K
Sidney Schechet	MD	Retina Specialist (Ophthalmology) Physician	$4.2M	$0
Chirag Patel	IL	Family Medicine Physician	$32.2K	$4.1M

Nearby Providers

Other providers in the same ZIP code as Mohamed Farhat, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Saint Joseph Regional Medical Center-south Bend Campus, Inc.	IN	General Acute Care Hospital	$0	$18.7M
Toxusa Labs LLC	IN	Clinical Medical Laboratory	$1.3M	$9.6M
Pic Indiana PC	IN	Urgent Care Clinic/Center	$0	$10.7M
Radiology, Inc	IN	Diagnostic Radiology Physician	$0	$6.8M
Miracle Lane Family Dentistry P.C.	IN	Dental Clinic/Center	$0	$5.1M
Michiana Eye Center LLC	IN	Ophthalmology Physician	$0	$5M
Saint Joseph Regional Medical Center-south Bend Campus, Inc.	IN	Family Medicine Physician	$0	$4.8M
Northern Indiana Interim Healthcare Company LLC	IN	Home Health Agency	$0	$4.5M
Del Pilar Medical & Urgent Care PC	IN	Geriatric Medicine (Family Medicine) Physician	$0	$3.6M
Michiana Hematology-oncology P C	IN	Medical Oncology Physician	$0	$3M

Mohamed Farhat — Billing Profile & Reimbursement Data

Sign up for Mohamed Farhat — Billing Profile & Reimbursement Data policy alerts

Mohamed Farhat — Billing Profile & Reimbursement Data

Sign up for Mohamed Farhat — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References